Latest

01.09.2023

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

Read Article
11.21.2022

Graybug and CalciMedica Enter into Definitive Merger Agreement

Read Article
08.31.2022

Scientific Inquirer: Industry Matters: From Elite Responders to M2 macrophages – OncoResponse’s approach to cancer immunotherapy

Read Article
08.09.2022

Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors

Read Article
08.02.2022

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis®

Read Article
06.02.2022

Cellworks: Predictions of Overall Survival And Progression-Free Survival For Therapeutic Interventions In Glioblastoma Multiforme

Read Article
06.02.2022

Cellworks Singula Therapy Response Index (TRI) Predicts Clinical Outcomes For Esophageal Adenocarcinoma: MyCare-004

Read Article
04.14.2022

Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer

Read Article
Up NextAbout Us